Takeda Reaffirms Oncology Goals With $8.8 Billion Millennium Acquisition
This article was originally published in PharmAsia News
Executive Summary
Takeda's acquisition of Millennium for $8.8 billion will extend the Japanese drug maker's presence in oncology and help stem the loss of revenues as key drugs go generic. Takeda announced plans to acquire the Cambridge, Mass.-based biotech April 10 for $25 per share, a 53 percent premium over the April 9 closing price
You may also be interested in...
Stockwatch: Valeant Attempts To Divert Attention
A well-orchestrated build-up to the annual J.P. Morgan Healthcare Conference and subsequent rush of fundraisings was helped by the acquisition of Ariad by Takeda early last week. But the good times were derailed by a drug-pricing diversion, unleashed by the US president-elect.
Japanese Pharmas Hit By Strong Yen: Japanese Pharma Earnings Roundup
TOKYO - As expected, top Japanese pharmaceutical players have reported lackluster April-June earnings as they struggled under the strong yen's weight, with three leading firms reiterating efforts to expedite launching products now in the pipelines
Japanese Pharmas Hit By Strong Yen: Japanese Pharma Earnings Roundup
TOKYO - As expected, top Japanese pharmaceutical players have reported lackluster April-June earnings as they struggled under the strong yen's weight, with three leading firms reiterating efforts to expedite launching products now in the pipelines